Cancer and neoplasms
Peanut Allergy Market to Accelerate Substantially by 2032, Examines DelveInsight | Leading Companies – Vedanta, Allergy, COUR Pharmaceutical, DBV, Aimmune, Novartis, NIAID, Alladapt Immunotherapeutics
Sep
New York, USA, Sept. 12, 2023 (GLOBE NEWSWIRE) — Peanut Allergy Market to Accelerate Substantially by 2032, Examines DelveInsight | Leading Companies – Vedanta, Allergy, COUR Pharmaceutical, DBV, Aimmune, Novartis, NIAID, Alladapt Immunotherapeutics
The dynamics of the peanut allergy market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, incremental healthcare spending worldwide, and the expected launch of emerging therapies.
DelveInsight’s Peanut Allergy Market Insights report includes a comprehensive understanding of current treatment practices, peanut allergy emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Peanut Allergy Market Report
- As per DelveInsight’s analysis, the peanut allergy market is anticipated to grow at a significant CAGR by 2032.
- As per DelveInsight’s estimates, in the United States, the prevalence of severe cases of peanut allergy is higher than mild-to-moderate cases.
- Leading peanut allergy companies such as Vedanta Biosciences, Inc., Allergy Therapeutics, COUR Pharmaceutical Development Company, Inc., ALK-Abelló A/S, Syneos Health, DBV Technologies, Aimmune Therapeutics, Inc., Novartis Pharmaceuticals, National Institute of Allergy and Infectious Diseases (NIAID), Alladapt Immunotherapeutics, Inc., and others are developing novel peanut allergy drugs that can be available in the peanut allergy market in the coming years.
- Some of the key therapies for peanut allergy treatment include VE416, VLP Peanut, CNP-201, Peanut SLIT-tablet, DBV712, AR101, Ligelizumab, Remibrutinib, Omalizumab, ADP101, and others.
Discover which therapies are expected to grab the major peanut allergy market share @ Peanut Allergy Market Report
Peanut Allergy Overview
Peanut allergy is a serious and potentially life-threatening condition that affects a significant portion of the population, particularly children. It is an immune response triggered by the consumption of peanuts or exposure to peanut proteins. The exact cause of peanut allergy is still under investigation, but it is generally believed to result from a combination of genetic and environmental factors.
Symptoms of peanut allergy can range from mild to severe, and they typically manifest within minutes to hours after exposure. Mild symptoms may include itching, hives, or a runny nose. More severe reactions can include difficulty breathing, swelling of the face and throat, abdominal pain, vomiting, diarrhea, and a drop in blood pressure. In extreme cases, peanut allergy can lead to anaphylaxis, a life-threatening reaction that requires immediate medical attention and might involve multiple organs.
Diagnosing peanut allergy involves a combination of medical history, physical examination, and allergy testing. Physicians will inquire about any previous allergic reactions, family history, and the timing of symptoms in relation to peanut consumption. Allergy tests, such as skin prick tests or blood tests measuring allergen-specific antibodies, are conducted to confirm the presence of peanut allergy.
Peanut Allergy Epidemiology Segmentation
The peanut allergy epidemiology section provides insights into the historical and current peanut allergy patient pool and forecasted trends for the seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The peanut allergy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Peanut Allergy Diagnosed Prevalent Cases
- Peanut Allergy Gender-specific Cases
- Peanut Allergy Age-specific Cases
- Peanut Allergy Severity-specific Cases
Download the report to understand which factors are driving peanut allergy epidemiology trends @ Peanut Allergy Epidemiological Insights
Peanut Allergy Treatment Market
Peanut avoidance has always been regarded as the first line of treatment for anyone at risk of developing a peanut allergy. However, in 2017, the National Institute of Allergy and Infectious Diseases (NIAID) completely reversed its recommendations for children at risk of peanut allergy after the Learning Early About Peanut Allergy (LEAP) trial demonstrated that children at high risk of developing a peanut allergy were less likely to develop an allergy if they were exposed to peanuts within the first 12 months of life. Antihistamines, injectable epinephrine, steroids, and bronchodilators are currently used to treat anaphylaxis in patients with mild, moderate, or severe peanut allergies.
Palforzia, developed by Aimmune Therapeutics, was approved by the FDA in 2020 and is the first oral immunotherapy for the treatment of peanut allergies. It is made up of carefully selected quantities of peanut powder taken orally and is intended for children and teenagers aged 4 to 17 who are allergic to peanuts. The goal of Palforzia is to desensitize youngsters to peanuts. It is only accessible via a Risk Evaluation and Mitigation Strategy (REMS). Oral Immunotherapy is administering modest quantities of peanut protein orally and gradually increasing them until a more substantial dose is attained and maintained. This therapy strategy tries to initially produce desensitization to the peanut allergen, which can provide some protection against the hazards of accidental exposure while on treatment, and then to induce longer-term tolerance.
To know more about peanut allergy treatment, visit @ Peanut Allergy Treatment Drugs
Key Peanut Allergy Therapies and Companies
- VE416: Vedanta Biosciences, Inc.
- VLP Peanut: Allergy Therapeutics
- CNP-201: COUR Pharmaceutical Development Company, Inc.
- Peanut SLIT-tablet: ALK-Abelló A/S/Syneos Health
- DBV712: DBV Technologies
- AR101: Aimmune Therapeutics, Inc.
- Ligelizumab: Novartis Pharmaceuticals
- Remibrutinib: Novartis Pharmaceuticals
- Omalizumab: National Institute of Allergy and Infectious Diseases (NIAID)
- ADP101: Alladapt Immunotherapeutics, Inc.
Learn more about the FDA-approved drugs for peanut allergy @ Drugs for Peanut Allergy Treatment
Peanut Allergy Market Dynamics
The peanut allergy market has undergone significant dynamics in recent years, reflecting the growing awareness and understanding of this potentially life-threatening condition. With an increasing number of reported cases of peanut allergies, there has been a notable shift in focus towards research, diagnostics, and treatment options. This surge in demand has prompted pharmaceutical companies and biotech firms to invest in the development of innovative therapies, including oral immunotherapies and desensitization techniques.
Furthermore, regulatory agencies have adapted to these changes by revising labeling requirements and allergen-related regulations to ensure consumer safety. The peanut allergy market has also seen the emergence of educational initiatives aiming to raise awareness about peanut allergies, thereby influencing purchasing decisions and shaping public attitudes. As a result, the peanut allergy market is experiencing a transformative phase, characterized by advancements in medical interventions, regulatory adaptations, and increased public consciousness.
However, several factors may impede the growth of the peanut allergy market in the coming years. One notable barrier is the complexity of developing safe and effective treatments due to the variability in individual allergic reactions. Clinical trials for new therapies must navigate stringent safety standards and demonstrate long-term efficacy, which can be time-consuming and expensive. Additionally, gaining regulatory approval for these novel treatments involves navigating a complex landscape, which often requires substantial resources and expertise.
Accessibility and affordability pose another challenge, as innovative treatments might not be accessible to all due to factors like healthcare disparities and high costs. Public awareness and understanding of peanut allergies also remain a barrier, as misconceptions and stigmas can affect the adoption of preventive measures and appropriate management strategies. These barriers collectively shape the trajectory of the peanut allergy market dynamics, requiring a multidisciplinary approach for sustainable progress.
| Peanut Allergy Report Metrics | Details |
| Study Period | 2019–2032 |
| Peanut Allergy Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Key Peanut Allergy Companies | Vedanta Biosciences, Inc., Allergy Therapeutics, COUR Pharmaceutical Development Company, Inc., ALK-Abelló A/S, Syneos Health, DBV Technologies, Aimmune Therapeutics, Inc., Novartis Pharmaceuticals, National Institute of Allergy and Infectious Diseases (NIAID), Alladapt Immunotherapeutics, Inc., and others |
| Key Peanut Allergy Therapies | VE416, VLP Peanut, CNP-201, Peanut SLIT-tablet, DBV712, AR101, Ligelizumab, Remibrutinib, Omalizumab, ADP101, and others |
Scope of the Peanut Allergy Market Report
- Therapeutic Assessment: Peanut Allergy current marketed and emerging therapies
- Peanut Allergy Market Dynamics: Attribute Analysis of Emerging Peanut Allergy Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Peanut Allergy Market Access and Reimbursement
Discover more about peanut allergy drugs in development @ Peanut Allergy Clinical Trials
Table of Contents
| 1. | Peanut Allergy Market Key Insights |
| 2. | Peanut Allergy Market Report Introduction |
| 3. | Peanut Allergy Market Overview at a Glance |
| 4. | Peanut Allergy Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Peanut Allergy Treatment and Management |
| 7. | Peanut Allergy Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Peanut Allergy Marketed Drugs |
| 10. | Peanut Allergy Emerging Drugs |
| 11. | Seven Major Peanut Allergy Market Analysis |
| 12. | Peanut Allergy Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Unmet Needs |
| 16. | SWOT Analysis |
| 17. | Appendix |
| 18. | DelveInsight Capabilities |
| 19. | Disclaimer |
| 20. | About DelveInsight |
Related Reports
Peanut Allergy Epidemiology Forecast
Peanut Allergy Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted peanut allergy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Peanut Allergy Pipeline
Peanut Allergy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key peanut allergy companies, including DBV Technologies, Regeneron Pharmaceuticals, Cour Pharmaceutical, HAL Allergy, InnoUp Farma S.L., Vedanta Biosciences, Astellas Pharma, Intrommune Therapeutics, Genentech, ASIT biotech, BlueWillow Biologics, Allergy Therapeutics, Alladapt Immunotherapeutics, Desentum, Camallergy, Prota Therapeutics, IgGenix, among others.
Food Allergy Market
Food Allergy Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key food allergy companies, including Aimmune Therapeutics, Inc., Novartis Pharmaceuticals, DBV Technologies, InnoUp Farma S.L., COUR Pharmaceutical Development Company Inc., Vedanta Biosciences, Inc., Regeneron Pharmaceuticals, Genentech, Inc., Rho Federal Systems Division, Inc., Alladapt Immunotherapeutics, Inc., Camallergy, among others.
Food Allergy Pipeline
Food Allergy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key food allergy companies, including Merck & Co, DBV technologies, Genentech, Camallergy, Regeneron Pharmaceuticals, InnoUp Farma, Aravax, Inimmune, Novartis Pharmaceuticals, Astrazeneca, Cour Pharmaceuticals, Siolta Therapeutics, Vedanta Biosciences, Mabylon, GI Innovation, among others.
Allergy Diagnostics Market
Allergy Diagnostics Market Insights, Competitive Landscape, and Market Forecast – 2028 report deliver an in-depth understanding, market trends, market drivers, market barriers, and key allergy diagnostics companies including HOB Biotech Group Corp., Ltd., Thermofisher Scientific, Siemens Healthineers, Danaher, Romer Labs Division Holding, EUROIMMUN Medizinische Labordiagnostika AG, HollisterStier Allergy, Eurofins Scientific, Omega Diagnostics Group plc, among others.
Other Trending Reports
Digestive System Fistula Market | Dementia With Diabetes Market | Leber’s Hereditary Optic Neuropathy Market | Pecoma Market | Adamantinoma Market | Pegfilgrastim Biosimilar Insight | Functional Constipation Market | DDR Defective Tumors Market | Nephrotic Syndrome Pipeline | Pelizaeus-Merzbacher Disease Market | Hepatic Impairment Market | Primary Ciliary Dyskinesia Market | Surgical Bleeding Market | Radiotherapy-Induced Oral Mucositis Market | Relapsed Chronic Lymphocytic Leukemia CLL Market | Galactosemia Market | Glabellar Lines Market | Homozygous Familial Hypercholesterolemia Market | HR Positive/ HER2 Negative Breast Cancer Market | Lebers Hereditary Optic Neuropathy LHON Market | Nonalcoholic Fatty Liver Disease NAFLD Market | Orthotic Devices Market | Polypoidal Choroidal Vasculopathy Market | Sporadic Inclusion Body Myositis Market | Warm Autoimmune Hemolytic Anemia Market | Acid Sphingomyelinase Deficiency ASMD Market | B-Cell Chronic Lymphocytic Leukemia Market | Coccidioidomycosis Market | Frontotemporal Dementia Pipeline | Granulomatosis With Polyangiitis Market | Malignant Pleural Mesothelioma Market | Nocturnal Enuresis Market | Postmyocardial Infarction Syndrome Market | Severe Acute Respiratory Syndrome Sars Coronavirus Infection Market | Typhoid Fever Market | Ventricular Dysfunction Market | Burkitt Lymphoma Market | Chronic Progressive Multiple Sclerosis Market | Emesis Market | Fenebrutinib Market | Gastric Neuroendocrine Tumors Market | Juvenile Rheumatoid Arthritis Market | Persistent Epithelial Defects Market | Post-Polycythemia Vera Myelofibrosis Market | Primary Mediastinal Large B-Cell Lymphoma Market | Spinocerebellar Ataxias Market | Systemic Inflammatory Response Syndrome Market | Triple Negative Breast Cancer Market | Visceral Pain Associated With GI Disorders Market | Adrenal Cortex Neoplasms Market | Adrenal Insufficiency Market | Artificial Lung Devices Market | Atopic Keratoconjunctivitis AKC Market | Autonomic Dysfunction Market | Bradycardia Treatment Devices Market | Bullous Pemphigoid Market | Cone Rod Dystrophy Market | Cutaneous Lupus Erythematosus Market | Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market | Dermal Regeneration Matrix Market | Heart Pump Devices Market | Hemiplegia Market | Hepatic Impairement Market | Immunologic Deficiency Syndrome Market | Implantable Infusion Pump Market | Menorrhalgia Market Size | Myocarditis Market | Myopia Treatment Devices Market | Ocular Hypertension Market
Related Healthcare Services
Healthcare Consulting
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
